Fate Therapeutics Inc

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

• ↑FDA cleared FT839 IND, enabling late-2026 basket trial in multiple autoimmune diseases.
• ↑FT819 Phase I data: all four lupus patients hit rCRISS ≥25 with mRSS improvement.
• ↓Q2 ’23 net loss of $52.8M and Q1 ’24 revenue plunged to $1.9M.